Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PXL 770

Next Previous
Drug Profile

PXL 770

Alternative Names: PXL-770

Latest Information Update: 17 Dec 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Poxel
  • Class Antihyperglycaemics; Cardiovascular therapies; Hepatoprotectants; Heterocyclic compounds; Naphthalenes; Potassium compounds; Pyridines; Small molecules; Urologics
  • Mechanism of Action AMP activated protein kinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Adrenoleucodystrophy; Autosomal dominant polycystic kidney disease
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Adrenoleucodystrophy; Non-alcoholic fatty liver disease
  • Phase I Autosomal dominant polycystic kidney disease
  • Preclinical Cardiomyopathies
  • No development reported Non-alcoholic steatohepatitis
  • Discontinued Type 2 diabetes mellitus

Most Recent Events

  • 16 Dec 2024 Poxel withdrwn a phase-II clinical trials in Adrenoleucodystrophy (In adults, In the elderly) in Germany, Netherlands, France, Spain, Belgium, Sweden, Denmark and Italy (PO) due to lack of funding to initiate the trial (NCT05146284)
  • 16 Feb 2024 Poxel has patent protection for PXL 770 in European Union
  • 31 Dec 2023 Poxel files for patent protection for PXL 770 in the US

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top